Multigut: The Effect of Micronutrient Supplementation on Gut Microbiome Composition and Function

Sponsor
University of Glasgow (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT05371704
Collaborator
(none)
24
1
2
16.1
1.5

Study Details

Study Description

Brief Summary

The main aim of this randomized crossover study is to explore the effect of micronutrient supplementation on gut microbiota composition and function in healthy volunteers. Participants will undertake two 10-day trials with a replicated diet separated by a 15-day washout period. For one of these trials, participants will take a daily over-the-counter multivitamin supplement. Faecal and urine samples will be collected at the start and end of each trial to assess changes in gut microbiota composition, urinary and faecal metabolomics, and targeted bacterial metabolites including short chain fatty acids, sulphide, and lactate.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Multivitamin Supplementation
  • Other: Dietary Replication
N/A

Detailed Description

Exploring the effect of habitual dietary patterns on human gut microbiota and on host health is an area of scientific interest and a major funding theme in UKRI. The main aim of this proof-of-concept study is to explore the effect of micronutrient supplementation on gut microbiota composition and function in healthy volunteers.

Participants will be asked to undertake two trials with 15 day washout in-between. If the participants are allocated to the "supplementation group" they will be asked to consume an over-the-counter multivitamin supplement for 10 days (1 tablet per day) in addition to their usual diet. Participants will provide faecal and urinary samples prior to initiation of the intervention and again at the end of the 10-day supplementation. During these 10 days participants will be asked to record the meals they consume on provided food diaries. If the participants are allocated to the "control group", participants will be asked to provide the same number of samples and at the same intervals as the supplementation group (i.e. at baseline and after 10 days) but without receiving micronutrient supplementation. Participants will also be asked to replicate as close as possible the diet they had followed during the first trial they were allocated. Between the two trials, participants will follow a wash-out period of 15 days with the aim of reverting the gut microbiota characteristics back to baseline levels.

The main outcome measures of this study are to assess changes in gut microbiota composition based on 16S rRNA gene amplicon sequencing, changes in urinary/faecal metabolomics, and changes in targeted bacterial metabolites (short chain fatty acids, sulphide, lactate).

Study Design

Study Type:
Interventional
Anticipated Enrollment :
24 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
None (Open Label)
Primary Purpose:
Basic Science
Official Title:
The Effect of Micronutrient Supplementation on Gut Microbiome Composition and Function
Actual Study Start Date :
Sep 28, 2021
Anticipated Primary Completion Date :
Sep 1, 2022
Anticipated Study Completion Date :
Feb 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Supplementation

In this arm of the study, participants will take 1 multivitamin pill each day for 10 days. If this is the participant's first trial, they will also record their diet in a 10-day estimated food diary. If this is the participant's second trial, they will replicate their diet recorded from their first trial.

Dietary Supplement: Multivitamin Supplementation
Participants will supplement daily with an over-the-counter oral multivitamin pill

Other: Dietary Replication
Patients will record their dietary intake in an estimated food diary during the first trial. During the second trial, participants will be asked to replicate their diet from the first trial

Other: Control

In this arm of the study, participants will not supplement with any multivitamin. If this is the participant's first trial, they will record their diet in a 10-day estimated food diary. If this is the participant's second trial, they will replicate the diet recorded from their first trial.

Other: Dietary Replication
Patients will record their dietary intake in an estimated food diary during the first trial. During the second trial, participants will be asked to replicate their diet from the first trial

Outcome Measures

Primary Outcome Measures

  1. Changes in gut microbiota composition during multivitamin supplementation [This will be assessed 4 times throughout the study. This will be assessed at the beginning (day 0) and end (day 10) of each 10-day trial.]

    Changes will be assessed via 16S rRNA gene amplicon sequencing from DNA extracts of faecal samples

  2. Changes in concentrations of faecal and urinary metabolites during multivitamin supplementation [This will be assessed 4 times throughout the study. This will be assessed at the beginning (day 0) and end (day 10) of each 10-day trial.]

    Concentration of several urinary and faecal metabolites will be assessed via 1H NMR spectroscopy in urine and faecal samples from study participants. Changes during multivitamin supplementation will be investigated.

  3. Changes in bacterial metabolites during multivitamin supplementation [This will be assessed 4 times throughout the study. This will be assessed at the beginning (day 0) and end (day 10) of each 10-day trial.]

    Changes in targeted bacterial metabolites including short chain fatty acids, sulphide, ammonia, lactate, succinate, ethanol

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Healthy adults >18 y
Exclusion Criteria:
  • History of previous major gut surgery,

  • Unstable weight,

  • Use of pre/probiotics, micronutrient supplements, antibiotics, or steroids the last 3 months

  • Participation in other research

Contacts and Locations

Locations

Site City State Country Postal Code
1 School of Medicine, University of Glasgow / New Lister Building, Glasgow Royal Infirmary Glasgow United Kingdom G312ER

Sponsors and Collaborators

  • University of Glasgow

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Dr Konstantinos Gerasimidis, Professor, University of Glasgow
ClinicalTrials.gov Identifier:
NCT05371704
Other Study ID Numbers:
  • Version 1
First Posted:
May 12, 2022
Last Update Posted:
May 12, 2022
Last Verified:
May 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No

Study Results

No Results Posted as of May 12, 2022